Page 41 - Read Online

Page 10 of 13 Briggs et al. J Cancer Metastasis Treat 2021;7:46 https://dx.doi.org/10.20517/2394-4722.2021.84

Table 5. PDL1 status as a predictive and prognostic biomarker
Biomarker Cohort therapy or histology PFS/DFS OS (CSS) n
PDL1 (neg vs. pos) [60] S HR = 0.70, 95%CI: 0.52-0.93 546
[9,28,45,50,51]
PDL1 (pos vs. neg) ccRCC Shorter, P = 0.0027 Shorter, P = 0.002 537
ICI, S, or E HR = 0.75, 95%CI: 0.63-0.89 HR = 0.72, 95%CI: 0.63-0.81 4635
P Median 15 months vs. 36 months, P = 0.03 221
S Median 15 months vs. 28 months, P = 0.03 232
S HR = 1.57, 95%CI: 1.16-2.14 804†
RR = 2.37, P < 0.001 306
(CSS RR = 3.92, P < 0.001)
[9,64]
PDL1 (neg) ICI (vs. S or E) HR = 0.73, 95%CI: 0.62-0.87 2597
N (vs. E) HR = 0.77, 95%CI: 0.60-0.97 575
[9,30,65-68]
PDL1 (pos) A + Ax (vs. S) HR = 0.63, 95%CI: 0.49-0.81 886‡
A + Ax (vs. S) HR = 0.62, 95%CI: 0.49-0.78 560
A + Ax vs. S HR = 0.61, 95%CI: 0.47-0.79 560
At + B (vs. S) HR = 0.74, 95%CI: 0.57-0.96 362
ICI (vs. S or E) HR = 0.68, 95%CI: 0.54-0.87 2038
N + Ip vs. S HR = 0.46, 95%CI: 0.31-0.68 214
Pm + Ax (vs. S) HR = 0.62, 95%CI: 0.47-0.80 HR = 0.54, 95%CI: 0.35-0.84 497
Sarcomatoid, At + B (vs. S) HR = 0.45, 95%CI: 0.26-0.77 86
PDL1 ≥ 5%, lymphocytes (vs. < 5%) [51,58] CSS RR = 4.53, P < 0.001 196
[50]
PDL1 H-Score > 55 and intratumor CD8- positive T-cell counts > 300 (vs. ≤ 55 and ≤ 300) P 9.6 months vs. 36.8 months 221
‡Total sample size of study (n of direct comparison not available). Grey Cell: Positive association; White Cell: negative association; A: avelumab; At: atezolumab; Ax: axitinib; B: bevacizumab; E: everolimus; ICI:
immune checkpoint inhibitor; Ip: ipilimumab; N: nivolumab; P: pazopanib; Pm: pembrolizumab; S: sunitinib; ccRCC: clear cell renal cell carcinoma; CSS: cancer specific survival; DFS: disease free survival; HR: hazard
ratio; OS: overall survival; PFS: progression free survival; RR: relative risk; PDL1: programmed death-ligand.

DECLARATIONS
Authors’ contributions
Contributed to conceptualization: Blute ML
Contributed to supervision: Blute ML
Contributed to writing - review and editing: Blute ML, Lee RJ, Cone EB, Briggs LG
Contributed to methodology supervision: Cone EB